MTF2 and cancer: Consistent with the rarity of MTF2 mutations in AML, the incidence of MTF2 mutations is very low across cancer types, with a recorded mutation rate of 1.5% observed among 10,953 patients encompassing 32 different cancer types (Figure 5A,B).